AlphaSIP designs a rapid diagnostic system for respiratory diseases that it intends to market globally

Presents its PneumoSIP project

AlphaSIP is working on the design and manufacture of its PneumoSIP, a device capable of detecting the presence of pneumococci in saliva in less than three hours. This nanochip is being developed as part of an international project in collaboration with the University of Zaragoza.

The development of this nanochips It is part of the project ECSEL InforMEDwhich seeks to establish a pilot micro-manufacturing line for medical devices that covers the entire innovation chain. UZ y AlphaSIP They are the only Spanish entities participating in this large-scale microelectronics manufacturing program.

PneumoSIP Development began on November 1st thanks to the support of the SME Instrument program, which rewards European SMEs with the greatest growth potential. AlphaSIP, which participates in several European projects, was selected from over 7 companies competing for funding. In total, the company will receive €3,7 million to finance development and clinical trial costs.

The system, which will represent significant savings for the medical environment and a major advance in improving patient treatment, is expected to be on the market in about two years, both in Europe and in other regions of the world.

Founded in 2008, AlphaSIP is a Aragonese biomedical company Focused on the design, development, production, and marketing of medical diagnostic devices, its products facilitate the immediate and effective detection of biomarkers and other substances, promoting improved healthcare and road safety. Their technology, Spanish and North American, is aimed at the creation of Microfluidic Platforms, which allow the detection of diseases at the point of origin, their first product being a Road Safety and Occupational Health System, capable of detecting drugs in saliva and urine.